AstraZeneca shares rise

AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising investor hopes that the impact of several probes in the country could be minor and leading its shares to rise about 5%.
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).
AstraZeneca shareholders say they need clarity on China investigations
AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets.
Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation. Read more here.
The inside story of Britain’s failure to clinch £450mn AstraZeneca deal
How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...
Inside AstraZeneca’s abandoned UK vaccine plant deal as Labour and Tories face questions over £450m collapse
AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...
FierceBiotech3d
AstraZeneca CEO defends 'fantastic' Alexion buyout in face of $753M hit from dropped drug
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...
Drugmaker AstraZeneca flags possible $4.5 million Chinese tax fine
AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its ...
AstraZeneca reports better than expected profit on higher cancer drug sales
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
AstraZeneca Expects Further Sales, Earnings Growth After Results Beat Market Views
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
AstraZeneca reports strong results boosted by promising trials
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...
Peer demands answers on AstraZeneca deal collapse
A Liberal Democrat peer has accused the government of favouring the south-east of England over Merseyside after AstraZeneca ...
AstraZeneca CEO: UK must improve investment environment
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...